TNFRSF4 and neoplasm: Thus, we reasoned that targeting OX40 with the agonistic antibody OX-86 could improve tumor rejection in mice treated with RT+CTLA4i, but this combination failed to show any benefits (Fig. 6b, c, Supplementary Fig. 17a).